Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP

Impaired cardiorenal response to acute saline volume expansion in preclinical systolic dysfunction (PSD) may lead to symptomatic heart failure. The objective was to determine if combination phosphodiesterase-V inhibition and exogenous B-type natriuretic peptide (BNP) administration may enhance cardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Siu-Hin, Torres-Courchoud, Isabel, McKie, Paul M., Slusser, Joshua P., Redfield, Margaret M., Burnett, John C., Hodge, David O., Chen, Horng H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
PRECLINICAL RESEARCH
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6939015/
https://www.ncbi.nlm.nih.gov/pubmed/31909303
http://dx.doi.org/10.1016/j.jacbts.2019.08.008
Descripción
Sumario:Impaired cardiorenal response to acute saline volume expansion in preclinical systolic dysfunction (PSD) may lead to symptomatic heart failure. The objective was to determine if combination phosphodiesterase-V inhibition and exogenous B-type natriuretic peptide (BNP) administration may enhance cardiorenal response. A randomized double-blinded, placebo-controlled study was conducted in 21 subjects with PSD and renal dysfunction. Pre-treatment with tadalafil and subcutaneous BNP resulted in improved cardiac function, as evidenced by improvement in ejection fraction, left atrial volume index, and left ventricular end-diastolic volume. However, there was reduced renal response with reduction in renal plasma flow, glomerular filtration rate, and urine flow. (Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure; NCT01544998)

Ejemplares similares